Questions on which the views of the Committee are sought:

i)               Does the report capture the most up to date information and details on benchmark dose modelling?

ii)              Are the Members content with the areas covered in the report?

iii)            Can the available BMD guidance and resources support the integration of new approach methodologies in future guidance?

iv)            Can BMD modelling provide a useful and practical tool that can be applied in a chemical risk assessment?

v)             Do Members have any examples of when this approach could be applied and or recommendations?

Do the Members have any other comments?

Secretariat

February 2024